[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371028-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371028-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","tumor-derived-lactate-fuels-the-stat3-lcn2-pathway-to-promote-bladder-cancer-malignancy-and-chemoresistance","Tumor-derived lactate fuels the STAT3-LCN2 pathway to promote bladder cancer malignancy and chemoresistance","","Bladder cancer progression is tied to metabolic alterations in the tumor microenvironment, especially elevated lactate. This study tests how exogenous lactate or inhibition of endogenous lactate production changes Lipocalin 2 (LCN2) expression, and evaluates STAT3 involvement using genetic knockdown and pharmacological inhibitors. Functional assays show that lactate-driven LCN2 promotes EMT, migration, stemness, and gemcitabine resistance, while LCN2 silencing restores chemosensitivity. Clinical correlations link higher LCN2 with advanced grade and poorer survival.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/tumor-derived-lactate-fuels-the-stat3-lcn2-pathway-to-promote-bladder-cancer-malignancy-and-chemoresistance/371028/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/tumor-derived-lactate-fuels-the-stat3-lcn2-pathway-to-promote-bladder-cancer-malignancy-and-chemoresistance/371028.png","ImageObject",300,407,{"name":42,"@type":43},"kopisore","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does tumor-derived lactate influence LCN2 expression in bladder cancer cells?","Question",{"text":63,"@type":64},"Tumor-derived lactate induces LCN2 expression by activating STAT3 signaling in bladder cancer cells.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What biological changes does LCN2 promote in bladder cancer?",{"text":68,"@type":64},"LCN2 promotes EMT, enhances cell migration, and increases stem cell-like properties, including higher stemness markers and sphere-forming ability.",{"name":70,"@type":61,"acceptedAnswer":71},"Does targeting the STAT3-LCN2 axis affect chemotherapy response?",{"text":72,"@type":64},"Yes. Disrupting STAT3 signaling reduces LCN2 levels, and LCN2 knockdown restores chemosensitivity by counteracting lactate-induced gemcitabine resistance.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371028,1791180505,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":108,"preview_page_count":33,"preview_urls":145},962090880963,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nTumor-derived lactate fuels the STAT3-LCN2 pathway to promote bladder cancer malignancy and chemoresistance  \nShih-YuYu1, Hao-Yi Li2, Chi-Yun Wang3,4, Wei-Jan Wang5, Shih-Hao Hsu1, Min-Chen Hsiang1, Ke-Xin Yee6, Kuen-Haur Lee6,7,8,9 & Yu-Cheng Lee1􀀍  \nBladder cancer progression is closely linked to metabolic changes within the tumor microenvironment (TME), particularly elevated lactate levels. Lipocalin 2 (LCN2), a protein involved in iron regulation, has been implicated in tumor progression in several cancers, but its regulatory mechanisms and role in bladder cancer remain unclear. Bladder cancer cell lines were treated with exogenous lactate or subjected to inhibition of endogenous lactate production to evaluate changes in LCN2 expression. The role of Signal Transducer and Activator of Transcription 3 (STAT3) was assessed using genetic knockdown and pharmacological inhibitors. Functional assays including migration, epithelial-tomesenchymal transition (EMT), sphere formation, and stemness marker analysis were performed to determine the biological effects of LCN2. Chemoresistance to gemcitabine was examined with and without LCN2 silencing. Clinically, LCN2 expression was significantly associated with the pathological relevance of bladder tumors. Lactate significantly induced LCN2 expression in bladder cancer cells through activation of STAT3 . Disruption of STAT3 signaling reduced LCN2 levels. High LCN2 expression correlated with advanced tumor grade, poor prognosis, and shorter overall survival. Functionally, LCN2 promoted EMT, enhanced cell migration, and increased stem cell-like properties, as evidenced by elevated stemness markers and sphere-forming ability. Moreover, lactate-induced LCN2 expression conferred resistance to gemcitabine treatment, while LCN2 knockdown restored chemosensitivity.  \nThis study identifies tumor-derived lactate as a key inducer of LCN2 expression via STAT3 activation in bladder cancer. LCN2 contributes to tumor aggressiveness, cancer stemness, and chemoresistance. Targeting the STAT3-LCN2 signaling axis may offer a promising therapeutic strategy to suppress bladder cancer progression and overcome treatment resistance within a lactate-rich TME.  \nKeywords Bladder cancer, Tumor microenvironment (TME), Lipocalin-2 (LCN2), Tumor-derived lactate, STAT3, Chemoresistance  \nAbbreviations  \nBLCANMIBCMIBCLCN2  \nSTAT3  \nBladder cancer  \nNon-muscle-invasive bladder cancer Muscle-invasive bladder cancer Lipocalin 2  \nSignal Transducer and Activator of Transcription 3  \n1Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, No. 250, Wuxing St., Xinyi Dist, Taipei 11031, Taiwan. 2Institute of Precision Medicine, College of Medicine, National SunYat-Sen University, Kaohsiung 804, Taiwan. 3International Ph. D. Program in Innovative Technology of Biomedical Engineering and Medical Devices, Ming Chi University of Technology, New Taipei City 24301, Taiwan. 4Research Center for Intelligent Medical Devices, Ming Chi University of Technology, New Taipei City 243303, Taiwan. 5Department of Biological Science and Technology, China Medical University, Taichung 40676, Taiwan. 6PhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Shuang Ho Campus, New Taipei city 235, Taiwan. 7TMU Research Center for Digestive Medicine, Taipei Medical University, Taipei 11031, Taiwan. 8Cancer Center, Wan Fang Hospital, Taipei Medical University, Taipei 11031, Taiwan. 9TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei 11031, Taiwan. 􀀍 email: [yclee0212@tmu.edu.tw](yclee0212@tmu.edu.tw)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nTME EMT LACSCs ECMLDHANGALGEPIA2  \nTCGAGTEx HPA MC-T2  \nIPA  \nPMN-MDSCs  \nTumor microenvironment Epithelial-to-mesenchymal transition Lactic acid  \nCancer st","cbCaimOU70ANdJ5I","https://ap.wps.com/l/cbCaimOU70ANdJ5I","pdf",2292535,16,"English","# Background\n## Bladder cancer and tumor microenvironment\n## Cancer stem cells and therapeutic implications\n# Tumor-derived lactate, STAT3 activation, and LCN2 regulation\n## Effects on EMT, migration, and stemness\n## Chemoresistance to gemcitabine\n# Clinical relevance and therapeutic outlook","[{\"question\":\"How does tumor-derived lactate influence LCN2 expression in bladder cancer cells?\",\"answer\":\"Tumor-derived lactate induces LCN2 expression by activating STAT3 signaling in bladder cancer cells.\"},{\"question\":\"What biological changes does LCN2 promote in bladder cancer?\",\"answer\":\"LCN2 promotes EMT, enhances cell migration, and increases stem cell-like properties, including higher stemness markers and sphere-forming ability.\"},{\"question\":\"Does targeting the STAT3-LCN2 axis affect chemotherapy response?\",\"answer\":\"Yes. Disrupting STAT3 signaling reduces LCN2 levels, and LCN2 knockdown restores chemosensitivity by counteracting lactate-induced gemcitabine resistance.\"}]","Tumor-derived lactate fuels the STAT3-LCN2 pathway to promote bladder cancer malignancy and chemoresistance | PDF",1790191064,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e628fc1a276569042cd1ac0aa17217cd.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3485eed10c07ad10bfc48ba0ef759127.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/01777f5009f895d2a638ffb99e36df9b.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c954cd63d3e8f00b962226dd00232e2.webp",980,1287]